Funding opportunities
Open and upcoming programs from Canadian funders and US federal grants (Grants.gov). Deadlines first, then rolling intakes.
NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
National Institutes of Health · Deadline 2027-10-18
The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.
Intervention Research to Improve Native American Health
National Institutes of Health · Deadline not published
The National Institute on Drug Abuse, along with other National Health Institutes, Centers, and Offices, seeks to advance its mission through the Intervention Research to Improve Native American Health (IRINAH), which aims to support: Research on the causes of health problems to inform the creation or refinement of interventions Studies that develop, adapt, or test interventions for health promotion, disease prevention, treatment, or recovery Research on the dissemination and implementation of strategies to overcome barriers to adopting, integrating, scaling up, and sustaining effective interventions. This initiative seeks interventions and related research that builds on community knowledge, strengths, and resilience to identify and rigorously test solutions to reduce morbidity and mortality in Native populations. Proposed interventions should be sustainable and flexible, so they can be adapted, shared, and expanded to other communities as appropriate. Grant authorities that allow NIDA to forecast this opportunity are as follows: 42 U.S.C 241 and 284
LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This program will encourage collaborations to perform effectiveness trials that incorporate implementation in real-world settings. Examples include combined efficacy-effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The intent is to bridge findings from traditional clinical trials to real-world implementation. The work will focus on populations across various points of care for prevention or treatment of HIV and its associated coinfections and comorbidities occurring in any age group. The goal of this program is to advance cross-cutting areas of HIV research, including clinical, behavioral and social sciences, epidemiology, and implementation science. This program aligns with the NIH mission to implement advances in HIV/AIDS research. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 an
Historically Black Colleges and Universities - Excellence in Research (HBCU - EiR)
U.S. National Science Foundation · Deadline 2027-10-19
The Historically Black Colleges and Universities - Excellence in Research (HBCU-EiR) program was established in response to direction provided in the Senate Commerce and Justice, Science and Related Agencies Appropriations Subcommittee Report (Senate Report 115-139), and is built on prior and continuing efforts by the National Science Foundation (NSF) to strengthen research capacity at Historically Black Colleges and Universities (HBCUs). This report provided guidance to NSF to establish the HBCU Excellence in Research program "to provide opportunities for both public and private HBCUs, particularly for those who have not been successful in larger NSF Research & Related Activities competitions, in order to stimulate sustainable improvement in their research and development capacity" ( https://congress.gov/congressional-report/115th-congress/senate-report/139/1 ). EiR supports such capacity building by funding research projects aligned with NSF's research programs. The program aims to establish stronger connections between researchers at HBCUs and NSF's research programs.
Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-10-19
The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly. Awards up to $650,000.
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-10-19
This Notice of Funding Opportunity (NOFO) solicits applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on early-stage development from prototyping to initial dissemination. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving research projects and other users throughout the development process mu Awards range from $50,000 to $300,000.
Mathematical Sciences Postdoctoral Research Fellowships (MSPRF)
U.S. National Science Foundation · Deadline 2027-10-20
The purpose of the Mathematical Sciences Postdoctoral Research Fellowships (MSPRF) is to support future leaders in mathematics and statistics by facilitating their participation in postdoctoral research environments that will have maximal impact on their future scientific development. There are two options for awardees: Research Fellowship and Research Instructorship. Awards will support research in areas of mathematics and statistics, including applications to other disciplines.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-10-20
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs. Awards up to $750,000.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-10-20
This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery. Awards up to $750,000.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-10-20
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier
National Institutes of Health · Deadline not published
The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks to advance its mission of supporting maternal, fetal, and child health by continuing to enhance the understanding of maternal, fetal, and child exposure to nutrients, metabolites, medications, supplements, microbiome-derived products, and environmental chemicals. This will be done by supporting a second phase of the Transporter Elucidation Network (TEN). This phase of the TEN will establish perinatal multi-barrier transport network frameworks to clarify how transporters and local biotransformation regulate these processes. Building on prior organ-focused models, methods, and datasets, this initiative will develop standards, resources, models, and prototype multi-compartment approaches spanning maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier. The initiative is expected to support a mechanistic understanding of transporter function, polarity, kinetics, and transformation capacity relevant to pregnancy, lactation, infant nutrition, pediatric pharmacology, and neurodevelopment. By emphasizing multi-barrier perinatal transporter frameworks this phase
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health · Deadline 2027-10-25
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
National Institutes of Health · Deadline 2027-10-25
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-10-25
Reissue of PAR-20-118. This Notice of Funding Opportunity (NOFO) encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-10-25
Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
National Institutes of Health · Deadline 2027-10-25
The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate or advanced science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole.Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htmThis REAP Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this NOFO, m Awards up to $375,000.
Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-10-28
The purpose of this notice of funding opportunity (NOFO) is to identify modifiable mechanisms and therapeutic targets to address central nervous system (CNS) complications associated with human immunodeficiency virus (HIV). The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. The goal of this NOFO is to advance therapeutic target, and intervention discovery to address the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction.
Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings--Implementation Science Network (PATC3H-IN)
National Institutes of Health · Deadline not published
The Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings–Implementation Science Network (PATC3H-IN) conducts implementation science (IS) research on adolescent HIV. PATC3H-IN develops scalable, low-resource care delivery models in low- and middle-income countries that can be adapted for marginalized and high-burden US populations. It aligns with NIH's Unified Strategy prioritizing IS to expand uptake of and access to HIV interventions. PATC3H-IN will study and test the impact of implementation strategies on adolescent HIV incidence, prevention uptake, and viral suppression, providing a strong evidence base for interventions that can be used in US-based programs. Resource-constrained, high-burden settings outside the US provide an unparalleled environment for adolescent HIV implementation science that aims to strengthen HIV care in the US. Higher HIV incidence and prevalence allow researchers to rigorously evaluate implementation strategies in large adolescent populations. The studies produce robust evidence on effectiveness, scalability, adaptation, and sustainability. These studies complement U.S.-based resea
National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-11-01
The objective of this Notice of Funding Opportunity (NOFO) is to continue to support laboratories that constitute a collaborative network, the NIDCD National Human Ear Resource Network, to serve as a national technological resource for auditory and vestibular researchers to use human inner and middle ear tissues for a range of basic and clinical studies to advance knowledge and treatment of auditory and vestibular disorders. Awards up to $450,000.
Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Research Sites (U24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The National Institute of Neurological Disorders and Stroke (NINDS), at the National Institutes of Health (NIH) seek to continue support for the Infrastructure for the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). NeuroNEXT conducts clinical trials and biomarker validation studies for neurological disorders in adult and pediatric populations. By offering infrastructure, expertise, and collaborative opportunities, NeuroNEXT accelerates innovation and impact, advancing the development of safe, effective neurotherapeutics for patients through high-quality evidence pathways. The program will encourage applications for network clinical research sites to support NeuroNEXT. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications for clinical research sites.